OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Ronald H. Spair sold 510,112 shares of OraSure Technologies stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the completion of the transaction, the chief financial officer now directly owns 208,606 shares in the company, valued at approximately $4,309,799.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of OraSure Technologies, Inc. (OSUR) traded up 1.23% during trading on Tuesday, reaching $21.46. 1,088,278 shares of the company were exchanged. The company has a 50 day moving average price of $17.63 and a 200-day moving average price of $13.64. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of 39.67 and a beta of 1.57. OraSure Technologies, Inc. has a one year low of $6.84 and a one year high of $21.55.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. OraSure Technologies’s revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $0.07 earnings per share. Equities analysts predict that OraSure Technologies, Inc. will post $0.48 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “OraSure Technologies, Inc. (OSUR) CFO Sells $10,538,913.92 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/orasure-technologies-inc-osur-cfo-sells-10538913-92-in-stock.html.

Several hedge funds have recently made changes to their positions in OSUR. First Mercantile Trust Co. purchased a new stake in shares of OraSure Technologies during the second quarter worth approximately $104,000. Victory Capital Management Inc. purchased a new stake in shares of OraSure Technologies during the first quarter worth approximately $100,000. Profund Advisors LLC purchased a new stake in shares of OraSure Technologies during the first quarter worth approximately $137,000. BNP Paribas Arbitrage SA raised its stake in shares of OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 9,723 shares during the last quarter. Finally, Private Advisor Group LLC raised its stake in shares of OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently commented on OSUR. Jefferies Group LLC lifted their price target on shares of OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, May 4th. Canaccord Genuity lifted their price target on shares of OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 12th. BidaskClub lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Stephens reissued an “overweight” rating and issued a $19.00 price target (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $15.46.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.